HCVC — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Nūmi uses cell culture technology to produce a new form of nutrition, aiming to replicate the benefits of breast milk as an alternative for parents and infants, with potential applications across other age groups.
BiotechFoodTechHealthtech
Co-investorsHeartcore CapitalKost CapitalSistaFinancière Saint JamesKima Ventures
Orakl Oncology, a spin-off from Gustave Roussy, builds an AI-and-biology platform that grows patient-derived tumor organoids and enriches them with genomic, transcriptomic, phenotypic, and clinical data to predict drug response and clinical trial outcomes.
AI & Machine LearningBiotechHealthtech
Diane-Laure Pagès(Founder)in
Co-investorsSistaVerve VenturesBpifranceSingularSpeedinvest
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.